04/07 Taiwan BIO Weekly
2026-04-07 |
| Taiwan BIO Weekly |
| Lotus Pharmaceutical Announces Acquisition of Sandoz AG's Philippines Business, Strengthening Its Presence in Southeast Asia Press release 2 April, 2026 Lotus Pharmaceutical Co., Ltd. (TW: 1795), a leading global pharmaceutical company, today announced that it has entered into an agreement to acquire Sandoz AG's Philippines business. Subject to closing conditions, the acquisition is expected to be completed in Q2 2026. More... |
| Ever Supreme Bio Technology revenue hits record high for March, up 15% YoY 1 April, 2026 Ever Supreme Bio Technology (TW: 6712) announced on 1st of April that its consolidated revenue for March reached NT$70.1 million, representing a 15.12% year-on-year increase and marking a record high for the same period. Cumulative consolidated revenue for the first quarter totaled NT$190 million. With steady growth in its CDMO business and key milestones in new drug development, the company's operational momentum continues to strengthen. The company noted that revenue growth in March was mainly driven by rising demand for regenerative medicine and cell therapy. More... (in Chinese) |
| Excelsior Biopharma adopts dual-engine precision medicine strategy to target Asian market 1 April, 2026 Excelsior Biopharma (TW: 6496) held its 40th anniversary celebration on 1st of April, while also inaugurating its new clinical laboratory and medical research center. The company officially launched its diagnostics plus R&D dual-engine strategy, signaling a transformation from a traditional niche medical supplier to a full-scale entry into the precision medicine and genetic testing markets. The company stated that it intended to integrate artificial intelligence with high-throughput genomic analysis technologies to enhance clinical application capabilities, expanding its footprint in Taiwan and extending into the broader Asian market. More... (in Chinese) |
| Enimmune's Enterovirus vaccine receives Macau approval, targets Hong Kong, Macau, and Southeast Asia markets 31 March, 2026 Enimmune (TW: 6564), a subsidiary of Adimmune (TW: 4142), announced that its Enterovirus 71 vaccine (EnVAX-A71), produced at Adimmune's Taichung factory, had received approval from the Macau Health Bureau for new drug registration, marking its second enterovirus vaccine approval. This certification will support expansion into the Hong Kong, Macau, and Southeast Asia markets. The Macau approval process began on February 21, 2025, with certification granted on 30th of March. Although Macau's population is small, recent outbreaks in local kindergartens and daycare centers have highlighted the need for enterovirus prevention, increasing local demand for vaccines. More... (in Chinese) |
| Taiwan to buy record 7.05 million flu vaccines for free annual program 31 March, 2026 Taiwan plans to buy a record 7.05 million influenza jabs for its annual publicly-funded vaccination campaign, including 200,000 enhanced vaccines for seniors in residential care facilities, the Centers for Disease Control (CDC) said Tuesday. Speaking at a weekly press conference, CDC Director-General Lo Yi-chun said Taiwan saw high demand for flu vaccines last year, when it purchased a total of 6.865 million doses. More... |
| Medimaging Integrated Solution’s bronchoscope enters the European market 30 March, 2026 Medimaging Integrated Solution (TW: 6796)'s announced that its proprietary disposable bronchoscope ECB100 has passed the EU Medical Device Regulation (EU MDR) review, securing a key entry ticket into the European market. As infection control standards in Europe continue to tighten, there is a clear shift in medical devices from reusable to single-use equipment, and Medimaging Integrated Solution stands to benefit from this trend, according to the company. More... (in Chinese) |
| AP Biosciences signs supplemental agreement with China's Tasly Pharmaceutical Group to advance global development of AP505 30 March, 2026 AP Biosciences (TW: 6945) has signed a supplemental agreement with Tasly Pharmaceutical Group regarding their collaboration on AP505, an innovative cancer immunotherapy. AP Biosciences stated that the agreement is intended to support licensing, strategic partnerships, and global business development of AP505 outside China, in alignment with ongoing and completed clinical trials by both parties. The agreement also clarifies the financial revenue-sharing arrangements and updates provisions from the original collaboration signed in 2019. More... (in Chinese) |
| Obigen Pharma targets US$10B botox market 30 March, 2026 Taiwan’s first novel botulinum toxin developer, Obigen Pharma (TW: 7876), is gaining international attention with its long-acting type A botulinum toxin, OBI-858. The company recently presented Phase II clinical trial results from Taiwan at BIO-Europe Spring in Lisbon and AMWC Monaco, with the results showing strong safety, efficacy, rapid onset, and long-lasting effects for glabellar lines. Leveraging these data and its novel ~760 kDa molecular design, Obigen Pharma has entered in-depth licensing discussions with over a dozen major international pharmaceutical and aesthetic medicine companies, positioning OBI-858 as a next-generation botulinum toxin product aligned with global market trends and potentially marking a new milestone for the company's international expansion. More... (in Chinese) |
| Following approval in Vietnam, Medigen's enterovirus vaccine submitted for market authorization review in Malaysia 28 March, 2026 Medigen Vaccine (TW: 6547) announced on 27th of March that it has submitted a New Drug Application (NDA) for its Envacgen enterovirus 71 (EV71) vaccine to the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia for regulatory review, aiming to capture the market for protecting approximately 400,000 newborns annually in the country. More... (in Chinese) |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2026 (15-19 July, 2026) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |